cnn tirzepatide A class-action lawsuit has been filed against CVS Caremark over its decision to stop covering Zepbound, Eli Lilly's blockbuster GLP-1 drug to treat obesity. When the major pharmacy benefit manager informed patients Zepbound: The newest obesity medication
Description
, Rupprecht L
The Danish company markets semaglutide for diabetes and obesity under the brand names Ozempic and Wegovy, respectively
Brand-name GLP-1 medications such as Ozempic, Wegovy, Mounjaro, and Zepbound are manufactured by pharmaceutical companies, undergo extensive FDA clinical trials, and are approved as finished drug products with fixed dosing options
They also started on weekly injections for 12 weeks before moving to monthly shots
